22 results on '"Przepiera-Będzak H"'
Search Results
2. A6.25 Serum concentrations of vascular endothelial growth factor in systemic lupus erythematosus – association with autoantibody profile and cardiovascular involvement
- Author
-
Fischer, K, Przepiera-Będzak, H, Ostanek, L, Walecka, A, Sawicki, M, Brzosko, I, and Brzosko, M
- Published
- 2015
- Full Text
- View/download PDF
3. P016 Vascular involvement in rheumatic diseases – the role of imaging and immunological biomarkers
- Author
-
Fischer, KM, primary, Przepiera-Będzak, H, additional, Brzosko, I, additional, Sawicki, M, additional, and Brzosko, M, additional
- Published
- 2019
- Full Text
- View/download PDF
4. A5.07 The role of immunologic and inflammatory factors in the risk of microvascular and macrovascular impairment development in systemic lupus erythematosus – preliminary data
- Author
-
Fischer, K, primary, Sawicki, M, additional, Chamiak-Ciemińska, K, additional, Stolarczyk, J, additional, Winikajtis-Burzyńska, A, additional, Milchert, M, additional, Ostanek, L, additional, Bobrowska-Snarska, D, additional, Kapłon, Ł, additional, Przepiera-Będzak, H, additional, Walecka, A, additional, Brzosko, I, additional, and Brzosko, M, additional
- Published
- 2016
- Full Text
- View/download PDF
5. AB0089 The association of interleukin 23 concentration with clinical course of systemic lupus erythematosus
- Author
-
Fischer, K.M., primary, Przepiera-Będzak, H., additional, Fliciński, J., additional, Walecka, A., additional, Sawicki, M., additional, Ostanek, L., additional, and Brzosko, M., additional
- Published
- 2013
- Full Text
- View/download PDF
6. Elevated Serum Levels of Soluble Transferrin Receptor Are Associated with an Increased Risk of Cardiovascular, Pulmonary, and Hematological Manifestations and a Decreased Risk of Neuropsychiatric Manifestations in Systemic Lupus Erythematosus Patients.
- Author
-
Winikajtis-Burzyńska A, Brzosko M, and Przepiera-Będzak H
- Subjects
- Humans, Iron, Receptors, Transferrin, Interleukin-6, Lung, Interleukin-4, Lupus Erythematosus, Systemic
- Abstract
The aim of this study was to analyze the relationship between the serum levels of soluble transferrin receptor (sTfR) and interleukin 4 (IL-4), and the disease activity and organ manifestations in SLE patients. We studied 200 SLE patients and 50 controls. We analyzed disease activity, organ involvement, serum sTfR, IL-4 and interleukin-6 (IL-6) levels, and antinuclear and antiphospholipid antibody profiles. The median serum levels of sTfR ( p > 0.000001) and IL-4 ( p < 0.00001) were higher in the study group than in the controls. SLE patients, compared to the controls, had significantly lower HGB levels ( p < 0.0001), a lower iron concentration ( p = 0.008), a lower value of total iron-binding capacity (TIBC) ( p = 0.03), and lower counts of RBC ( p = 0.004), HCT ( p = 0.0004), PLT ( p = 0.04), neutrophil ( p = 0.04), and lymphocyte ( p < 0.0001). Serum sTfR levels were negatively correlated with lymphocyte ( p = 0.0005), HGB ( p = 0.0001) and HCT ( p = 0.008), and positively correlated with IL-4 ( p = 0.01). Elevated serum sTfR > 2.14 mg/dL was associated with an increased risk of myocardial infarction (OR: 10.6 95 CI 2.71-464.78; p = 0.001), ischemic heart disease (OR: 3.25 95 CI 1.02-10.40; p = 0.04), lung manifestations (OR: 4.48 95 CI 1.44-13.94; p = 0.01), and hematological manifestations (OR: 2.07 95 CI 1.13-3.79; p = 0.01), and with a reduced risk of neuropsychiatric manifestations (OR: 0.42 95 CI 0.22-0.80; p = 0.008). Serum IL-4 was negatively correlated with CRP ( p = 0.003), and elevated serum IL-4 levels > 0.17 mg/L were associated with a reduced risk of mucocutaneous manifestations (OR: 0.48 95 CI 0.26-0.90; p = 0.02). In SLE patients, elevated serum levels of sTfR were associated with an increased risk of cardiovascular, pulmonary, and hematological manifestations, and with a decreased risk of neuropsychiatric manifestations. In contrast, elevated serum IL-4 levels were associated with a decreased risk of mucocutaneous manifestations.
- Published
- 2023
- Full Text
- View/download PDF
7. Increased Serum Interleukin 10 Levels Are Associated with Increased Disease Activity and Increased Risk of Anti-SS-A/Ro Antibody Positivity in Patients with Systemic Lupus Erythematosus.
- Author
-
Winikajtis-Burzyńska A, Brzosko M, and Przepiera-Będzak H
- Subjects
- Humans, Infant, Newborn, Leukopenia blood, Leukopenia immunology, Autoantibodies immunology, Interleukin-10 blood, Interleukin-10 immunology, Interleukin-6 blood, Interleukin-6 immunology, Lupus Erythematosus, Systemic immunology
- Abstract
Interleukin 10 (IL-10) plays a role in inflammation and cell-type responses. The anti-SS-A/Ro antibody contributes to leucopenia, and cutaneous and neonatal lupus., Objectives: To evaluate the association between serum IL-10 levels and autoantibodies, disease activity and organ involvement in systemic lupus erythematosus (SLE) patients., Patients and Methods: We studied 200 SLE patients and 50 controls. We analyzed organ involvement, disease activity, serum IL-10 and interleukin-6 (IL-6) levels, and antinuclear and antiphospholipid antibody profiles., Results: Serum IL-10 and IL-6 levels were higher in SLE patients than in controls (all p < 0.00001). Serum IL-10 levels were positively correlated with IL-6 ( p < 0.00001), CRP ( p < 0.00001), fibrinogen ( p = 0.003), and ESR ( p < 0.00001), and negatively correlated with hemoglobin ( p = 0.0004) and lymphocytes ( p = 0.01). Serum IL-6 levels were positively correlated with CRP ( p < 0.00001), fibrinogen ( p = 0.001), and ESR ( p < 0.00001); and negatively correlated with hemoglobin ( p = 0.008) and lymphocytes ( p = 0.03). Elevated serum IL-10 levels were associated with an increased risk of anti-SS-A/Ro antibody positivity ( p = 0.03). Elevated serum IL-6 levels were associated with an increased risk of heart ( p = 0.007) and lung ( p = 0.04) involvement., Conclusions: In SLE patients, increased serum IL-10 levels were associated with increased disease activity and risk of anti-SS-A/Ro antibody positivity.
- Published
- 2023
- Full Text
- View/download PDF
8. Anti-Phosphatidylethanolamine and Anti-Phosphatidylserine Antibodies-Association with Renal Involvement, Atherosclerosis, Cardiovascular Manifestations, Raynaud Phenomenon and Disease Activity in Polish Patients with Systemic Lupus Erythematosus.
- Author
-
Fischer K, Przepiera-Będzak H, Brzosko I, Sawicki M, Walecka A, and Brzosko M
- Subjects
- Humans, Animals, Phosphatidylserines, Carotid Intima-Media Thickness, Smoking, Antibodies, Antineutrophil Cytoplasmic, Poland, Biomarkers, DNA, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome diagnosis, Lupus Erythematosus, Systemic complications, Atherosclerosis complications, Raynaud Disease complications, Hominidae
- Abstract
Objective: To evaluate the association between anti-phosphatidylethanolamine (aPE) and anti-phosphatidylserine (aPS) antibodies and cardiovascular risk, organ involvement and disease activity in systemic lupus erythematosus (SLE) patients., Methods: We studied 93 SLE patients and 30 controls. We analyzed levels of anti-phospholipid antibodies, including aPS and aPE, the profiles of antinuclear, anti-neutrophil cytoplasmic (ANCA) and anti-endothelial antibodies, carotid intima-media thickness (cITM) and atherosclerotic plaque presence, ankle-brachial and high resistance indices, atherosclerotic risk factors, organ manifestations and treatment., Results: Levels of aPS and aPE were significantly higher in SLE patients in comparison with the controls ( p = 0.038 and p = 0.044, respectively). aPS was associated with the risk of Raynaud's phenomenon ( p = 0.021) development. aPE increased the risk of renal involvement ( p = 0.049), cerebral stroke ( p = 0.050), high vlues of cIMT ( p = 0.041) development as well as occurrence of selected serological markers associated with activity of the disease such as anti-double stranded DNA ( p = 0.021). The long duration of regular smoking ( p = 0.021) and the high number of cigarettes/day ( p = 0.015) were significantly associated with the risk of aPE occurrence., Conclusions: Patients with aPS and aPE are at risk of vascular involvement. Especially the presence of aPE may significantly increase the risk of thrombotic complications development in SLE patients without classical serological markers of APS. Finally, aPE might be used as a marker of disease activity and risk of renal injury development in this patient group. The classical atherosclerotic markers including lipid indices play an important role in complex analysis of cardiovascular risk in lupus patients and enable to identify patients at the highest risk and implement effective preventive, diagnostic and therapeutic procedures.
- Published
- 2022
- Full Text
- View/download PDF
9. Axial spondyloarthritis and inflammatory bowel disease: association between disease activity and endothelial dysfunction markers.
- Author
-
Przepiera-Będzak H, Fischer K, and Brzosko M
- Subjects
- Adult, Biomarkers blood, Blood Sedimentation, C-Reactive Protein analysis, Case-Control Studies, Female, Humans, Inflammatory Bowel Diseases complications, Interleukin-6 blood, Interleukin-8 blood, Male, Middle Aged, Axial Spondyloarthritis complications, Inflammatory Bowel Diseases diagnosis
- Abstract
Objective: We aimed to assess patients with axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) for disease activity and serum markers of endothelial dysfunction., Methods: We studied 161 patients (123 males, 38 females) with axSpA: 153 with ankylosing spondylitis and 8 with non-radiographic axSpA, and 30 healthy controls (HC). We collected: age; sex; disease duration; extra-articular symptoms (IBD and acute anterior uveitis), comorbidities; human leukocyte antigen B27 status; and treatment. We measured serum interleukin (IL)-6, interleukin-18, IL-23, vascular endothelial growth factor (VEGF) epidermal growth factor (EGF), asymmetric dimethylarginine (ADMA), endothelin-1 (ET-1), and fetuin-A levels., Results: IBD was diagnosed in 19 (11.8%) patients with axSpA. Compared to patients with axSpA without IBD, those with IBD had higher serum C-reactive protein (CRP) level (p = 0.05), erythrocyte sedimentation rate (ESR) (p = 0.005), and serum ET-1 levels (p = 0.01). In patients with axSpA and IBD, ET-1 levels correlated positively with CRP level (p = 0.006) and ESR (p = 0.02), and ADMA levels with visual analog scale scores (p = 0.01). Patients with axSpA and IBD had higher serum levels of IL-6 (p = 0.01), IL-18 (p = 0.005), and ADMA (p = 0.01) and lower serum levels of fetuin-A (p = 0.01) than did controls., Conclusions: Patients with axSpA and IBD had higher levels of disease activity, as assessed by ESR and CRP and ET-1 levels, than did patients with axSpA without IBD. Compared to HC, patients with axSpA and IBD had increased IL-18, ADMA levels and decreased fetuin-A level., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
10. Risk factors for SARS‑CoV-2 infection in patients with rheumatic diseases.
- Author
-
Snarska W, Jurkowska Z, Bobrowska-Snarska D, Brzosko M, and Przepiera-Będzak H
- Subjects
- Humans, Risk Factors, SARS-CoV-2, COVID-19, Rheumatic Diseases complications
- Published
- 2021
- Full Text
- View/download PDF
11. SAPHO syndrome: pathogenesis, clinical presentation, imaging, comorbidities and treatment: a review.
- Author
-
Przepiera-Będzak H and Brzosko M
- Abstract
Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a constellation of dermatological and osteoarticular symptoms. The pathogenesis of SAPHO is unknown, but infectious, genetic, immunological and environmental factors may play a role. SAPHO is classified along two different spectrums: pustulo-psoriatic hyperostotic spondyloarthritis and chronic recurrent multifocal osteomyelitis. The typical skin lesions are palmoplantar pustulosis and acne. The sign of arthritis is involvement of the anterior chest wall, most often the sternoclavicular joints. There are no standard treatment recommendations, but nonsteroidal anti-inflammatory drugs, sulfasalazine, methotrexate, antibiotics and biological drugs can be considered., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2021 Termedia Sp. z o. o.)
- Published
- 2021
- Full Text
- View/download PDF
12. An expert opinion of the Polish Cardiac Society Working Group on Pulmonary Circulation and the Polish Society for Rheumatology on the diagnosis and treatment of pulmonary hypertension in patients with connective tissue disease.
- Author
-
Mularek-Kubzdela T, Ciurzyński M, Kowal Bielecka O, Kasprzak JD, Kopeć G, Mizia-Stec K, Mroczek E, Lewicka E, Skoczylas I, Grabka M, Furdal M, Florczyk M, Brzosko M, Batko B, Przepiera-Będzak H, Samborski W, and Kucharz EJ
- Subjects
- Expert Testimony, Humans, Poland, Pulmonary Circulation, Connective Tissue Diseases complications, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary drug therapy, Hypertension, Pulmonary etiology, Rheumatology
- Abstract
Systemic connective tissue diseases (CTDs) comprise a large group of diseases that are auto-immune in nature and characterized by the involvement of multiple systems and organs. Pul-monary hypertension (PH) of various etiologies may develop in the course of CTD, including pulmonary arterial hypertension (PAH), PH secondary to the lung disease, postcapillary PH in the course of left heart disease, and chronic thromboembolic pulmonary hypertension (CTEPH). In addition, the different forms of PH may coexist with each other. Among patients with CTD, PAH occurs most commonly in those with systemic sclerosis, where it affects ap-proximately 8%-12% of patients. The prognosis in patients with untreated PAH is very poor. It is particularly important to identify the high-risk CTD-PAH population and to perform effi-cient and accurate diagnostics so that targeted therapy of the pulmonary arteries can be intro-duced. Echocardiography is used to screen for PH, but clinical and echocardiographic suspicion of PH always requires confirmation by right heart catheterization. Confirmation of PAH ena-bles the initiation of life-prolonging pharmacological treatment in this group of patients, which should be administered in referral centers. Drugs available for pharmacological management include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclins.
- Published
- 2021
- Full Text
- View/download PDF
13. Serum interleukin-23 protects, whereas methotrexate treatment stimulates selected components of the metabolic syndrome in patients with SAPHO syndrome.
- Author
-
Przepiera-Będzak H, Fischer K, and Brzosko M
- Abstract
Introduction: The aim of the study was to evaluate the impact of disease activity, selected serum cytokines, and therapy on metabolic syndrome (MetS) components in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome., Material and Methods: We studied 46 SAPHO patients (40 women, 6 men). We recorded age, sex, disease duration, arthritis localization, type of skin changes, bone scintigraphy results, comorbidities, BASDAI, VAS, and treatment. We measured erythrocyte sedimentation rate, C-reactive protein, lipid profile, serum IL-6, IL-18, IL-23, endothelin-1, vascular endothelial growth factor, and epidermal growth factor (EGF)., Results: 97.8% of patients had sternoclavicular joint arthritis, 91.3% of patients palmoplantar pustulosis. In 65.2% of SAPHO patients skin changes and arthritis started simultaneously. Apart from non-steroidal anti-inflammatory drugs, patients were treated with methotrexate (41.3%), sulfasalazine (41.3%), and antibiotics (39.1%). 19.5% of patients met MetS criteria. Serum IL-23 correlated positively with total cholesterol (TC; p = 0.02) and high-density lipoprotein cholesterol (HDL-C) ( p = 0.01) in the SAPHO group. There was a negative correlation between HDL-C and BASDAI ( p = 0.02). Patients treated with methotrexate had higher triglyceride ( p = 0.01) and low-density lipoprotein cholesterol (LDL-C) ( p = 0.01) levels. There was a negative correlation between TC and EGF ( p = 0.03). Increased prevalence of autoimmune diseases and depression was observed in SAPHO patients., Conclusions: Serum IL-23 protects, whereas methotrexate treatment stimulates selected components of the MetS in patients with SAPHO syndrome., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2018 Termedia & Banach.)
- Published
- 2018
- Full Text
- View/download PDF
14. Clinical symptoms, imaging, and treatment of SAPHO syndrome: a single‑center study of 52 cases.
- Author
-
Przepiera-Będzak H and Brzosko M
- Subjects
- Acquired Hyperostosis Syndrome diagnostic imaging, Acquired Hyperostosis Syndrome pathology, Acquired Hyperostosis Syndrome therapy, Adult, Female, Humans, Male, Middle Aged, Acquired Hyperostosis Syndrome diagnosis
- Published
- 2018
- Full Text
- View/download PDF
15. Results from Polish Spondyloarthritis Initiative registry (PolSPI) - methodology and data from - the first year of observation.
- Author
-
Guła Z, Barczyńska T, Brzosko M, Gąsowski J, Jeka S, Jodłowska-Cicio K, Kwaśny-Krochin B, Leszczyński P, Lubiński Ł, Łosińska K, Pawlak-Buś K, Przepiera-Będzak H, Samborski W, Schlabs M, Siedlar M, Sikorska D, Świerkot J, Węgierska M, Wiland P, and Korkosz M
- Abstract
Objectives: Report on one-year results from the Polish Spondyloarthritis Initiative registry (PolSPI), containing the cross-sectional analysis of clinical and imaging data as well as database methodology., Material and Methods: The PolSPI registry includes patients with axial (axSpA) and peripheral (perSpA) spondyloarthritis according to ASAS classification criteria, and/or patients with ankylosing spondylitis according to modified New York criteria, psoriatic arthritis according to CASPAR criteria, arthropathy in inflammatory bowel disease, reactive arthritis, juvenile spondyloarthritis or undifferentiated spondyloarthritis. Epidemiologic data and history of signs, symptoms and treatment of spondyloarthritis are collected and assessment of disease activity is performed. Radiographic images of sacroiliac joint, cervical and lumbar spine, and results of bone densitometry are collected. Every 6 months blood samples for inflammatory markers, and for long-term storage are taken., Results: During a one-year period from September 2015 to August 2016, 63 patients were registered on an electronic database; 44 (69.8%) of patients were classified as axial spondyloarthritis (axSpA) and 19 (30.2%) as peripheral spondyloarthritis (perSpA) according to ASAS criteria. Statistically significant differences between axSpA and perSpA were discovered in the percentage of HLA-B27 antigen occurrence (92.6% and 50%, respectively), BASDAI (2.8% and 4.1%, respectively), DAS 28 (2.66% and 4.03%, respectively), percentage of peripheral arthritis (20% and 88.8%, respectively), enthesitis (26.7% and 70.6%, respectively), dactylitis (6.7% and 88.9%, respectively), as well as extra-articular symptoms: acute anterior uveitis (26.7% and 5.6%, respectively) and psoriasis (6.9% and 55.6%, respectively). Patients with axSpA had significantly higher mean grade of sacroiliac involvement according to New York criteria, higher mSASSS score, and lower T-score in femoral neck in bone densitometry., Conclusions: At the early stage of the disease patients with axSpA compared to those with perSpA, have more advanced structural damage of sacroiliac joints and spine, and lower bone mineral density in the femoral neck. In the upcoming years the PolSPI registry will prospectively follow-up patients with SpA, recording response to treatment and carrying out research on interaction of inflammation and bone remodelling., Competing Interests: The authors declare no conflict of interest.
- Published
- 2017
- Full Text
- View/download PDF
16. Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease.
- Author
-
Fischer K, Przepiera-Będzak H, Sawicki M, Walecka A, Brzosko I, and Brzosko M
- Subjects
- Adult, Autoantibodies blood, Female, Humans, Lupus Nephritis immunology, Male, Middle Aged, Obesity immunology, Peripheral Vascular Diseases immunology, Plaque, Atherosclerotic etiology, Interleukin-23 blood, Lupus Erythematosus, Systemic immunology, Lupus Nephritis etiology, Obesity etiology, Peripheral Vascular Diseases etiology
- Abstract
Objectives: To analyze the correlation between the serum concentration of interleukin- (IL-) 23 and atherosclerotic changes, traditional atherosclerotic risk factors, the autoantibody profile, and involvement of selected organs in systemic lupus erythematosus (SLE) patients., Patients and Methods: We studied 94 SLE patients and 27 controls. We analyzed the IL-23 serum concentration, autoantibodies, carotid intima-media thickness and atherosclerotic plaque, the ankle-brachial index, atherosclerotic risk factors, and organ manifestations., Results: Concentrations of IL-23 significantly differed between SLE patients and the controls ( p = 0.0015). On the basis of multivariate stepwise analysis, we revealed that high levels of IL-23 were associated with atherosclerotic plaque in common femoral arteries (OR = 12.67; 95% CI: 1.41-113.84), lupus nephritis (OR = 3.69; 95% CI: 1.16-12.22), and obesity (OR = 4.21; 95% CI: 1.40-12.67). Autoantibodies related to IL-23 were anti-phosphatidylethanolamine antibodies (OR = 11.06; 95% CI: 1.24-98.65) and anti-SS-B/La antibodies (OR = 15.43; 95% CI: 1.73-137.25)., Conclusions: IL-23 may be involved in lupus nephritis pathogenesis. Through its association with obesity and selected antiphospholipid antibodies, IL-23 might promote a hypercoagulable state contributing to atherothrombosis development in SLE patients.
- Published
- 2017
- Full Text
- View/download PDF
17. Antiphospholipid Syndrome with Antiβ2glicoprotein-1 Antibodies as the Cause of Recurrent Tibial Vein Thrombosis in SAPHO syndrome.
- Author
-
Przepiera-Będzak H and Brzosko M
- Subjects
- Adult, Antiphospholipid Syndrome immunology, Enoxaparin administration & dosage, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Rare Diseases, Recurrence, Risk Assessment, Ultrasonography methods, Venous Thrombosis etiology, Acquired Hyperostosis Syndrome complications, Acquired Hyperostosis Syndrome diagnosis, Antibodies, Anticardiolipin blood, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome diagnosis, Venous Thrombosis diagnostic imaging
- Abstract
The antiphospholipid antibody syndrome is defined by the presence of antiphospholipid antibodies in patients with recurrent venous or arterial thromboembolism (1). SAPHO syndrome is a rare disease, characterized by specific clinical manifestations of synovitis, acne pustulosis, hyperostosis, and osteitis. It is a disease that manifests with a combination of osseous and articular manifestations associated with skin lesions (2). Venous thrombosis complicating SAPHO syndrome seems to be uncommon with an unclear pathogenesis (3-9). Coexistence of antiphospholipid syndrome and SAPHO syndrome was not previously mentioned in literature. A 33-year-old white woman was diagnosed with SAPHO syndrome at the age of 31. The patient was previously diagnosed with polycystic ovary syndrome and depressive syndrome. She was treated with sulfasalazin (2 g daily) and methotrexate (20 mg weekly). Seven months before admission to our department she experienced an episode of deep vein thrombosis of the left leg, successfully treated with subcutaneous enoxaparin sodium (40 mg daily) that was continued for the following 6 months as secondary prophylaxis. Pustular skin changes on palmar surface of the hands and plantar surface of the feet (characteristic for palmo-plantar pustulosis), tenderness of sterno-clavicular joints, swelling and restricted motion of both wrists, and pain on motion in both elbows, shoulders, knees, and ankles were found on physical examination. There was also a moderate amount of effusion in her left knee. There was a 3-centimeter difference between the circumferences of the shins. The level of C reactive protein was increased (6.21 mg/L). The patient was positive for antiβ2glicoprotein-1 (anti-β2G-1) antibodies. Tests for anticardiolipin antibodies (aCL), antiannexin V antibodies, antiphosphatidylserine antibodies (aPS), and antiprothrombin antibodies (aPT) were negative. Prothrombin time, activated partial thromboplastin time, and D-dimer level were normal, and lupus anticoagulant was not present. Serum concentrations of protein C, protein S, factor V Leiden, and antiprothrombin III levels were normal. Tests for antinuclear antibodies, rheumatoid factor, and HLA-27 antigen were negative. Serum vascular endothelial growth factor (VEGF) level was 360 pg/mL, serum epidermal growth factor (EGF) level was 566 pg/mL. Bacteria culture of discharge from pustules was negative. Doppler ultrasound examination of the left leg confirmed thrombosis of one the posterior tibial veins at its lower third. Subcutaneous enoxaparin sodium was started and later replaced with acenocumarol. The dose of sulfasalazin was increased to 3.0 g daily, and azithromycin 1.0 g daily once a week (for 8 weeks) was added. After 3 months, the patient reported reduction of joint pain. The follow-up Doppler ultrasound examination of the left leg revealed resolution of thrombosis. Three months later, the anti-β2G-1 antibodies were positive, so the patient met the criteria of antiphospholipid syndrome (1). The treatment with acenocumarol was continued and hydroxychlorochine was started. Venous thrombosis complicating SAPHO syndrome seems to be uncommon with an unclear pathogenesis. There were reports of thrombosis of the following veins: subclavian, mediastinan, iliac, and the superior vena cava (3-8). We have diagnosed recurrent tibial vein thrombosis in a patient with SAPHO syndrome in the course of antiphospholipid syndrome. There were suggestions that the reason for some cases of vein thrombosis in SAPHO syndrome is a pressure of the hyperostotic skeleton or inflamed soft tissue on the vein walls (3,4,6,10), which was not the case in our patient. Legoupil et al. (6) suggested that the reason for iliac vein thrombosis in SAPHO syndrome was an impressive extension of the inflammatory process to the soft tissues within the lumbar spine. That patient was negative for aCL antibodies (6). Kawabata et al. (7) suspected that aCL antibodies could be the reason for thrombosis in this syndrome, but the patient with multiple venous thrombosis presented in his case report was negative for aCL antibodies; however, he was not tested for anti-β2G-1 antibodies. There was a paper demonstrating increased level of aCL antibodies in 5 of 12 patients with SAPHO syndrome (11). In our observations of 17 patients with SAPHO syndrome, only 1 had increased level of aCL antibodies without symptoms of thrombosis (12). That patient was negative for aCL antibodies, aPT antibodies, aPS antibodies, and antiphosphatidylserine antibodies, but she was positive twice for anti-β2G-1 antibodies. The presence of anti-β2G-1antibodies may be caused by an infectious agent, but in our case bacteria culture of the discharge from pustules was negative. One year after the first episode of deep vein thrombosis, our patient met the criteria of antiphospholipid syndrome. We conclude that antiphospholipid syndrome, especially the presence of anti-β2G-1 antibodies, could be the cause of increased risk of vein thrombosis in SAPHO syndrome.
- Published
- 2016
18. Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome.
- Author
-
Przepiera-Będzak H, Fischer K, and Brzosko M
- Subjects
- Acquired Hyperostosis Syndrome diagnosis, Adult, Arthritis, Psoriatic diagnosis, Biomarkers blood, Case-Control Studies, Female, Humans, Male, Middle Aged, Spondylitis, Ankylosing diagnosis, Acquired Hyperostosis Syndrome blood, Arthritis, Psoriatic blood, Endothelin-1 blood, Intercellular Adhesion Molecule-1 blood, Interleukin-18 blood, Spondylitis, Ankylosing blood
- Abstract
To examine serum interleukin 18 (IL-18), fetuin-A, soluble intercellular adhesion molecule-1 (sICAM-1), and endothelin-1 (ET-1) levels in ankylosing spondylitis (AS), psoriatic arthritis (PsA), and Synovitis Acne Pustulosis Hyperostosis Osteitis syndrome (SAPHO). We studied 81 AS, 76 PsA, and 34 SAPHO patients. We measured serum IL-18, fetuin-A, sICAM-1, ET-1, IL-6, IL-23, vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). IL-18 levels were higher in AS (p = 0.001), PsA (p = 0.0003), and SAPHO (p = 0.01) than in controls, and were positively correlated with CRP (p = 0.03), VEGF (p = 0.03), and total cholesterol (TC, p = 0.006) in AS and with IL-6 (p = 0.03) in PsA. Serum fetuin-A levels were lower in AS (p = 0.001) and PsA (p = 0.001) than in controls, and negatively correlated with C-reactive protein (CRP) in AS (p = 0.04) and SAPHO (p = 0.03). sICAM-1 positively correlated with CRP (p = 0.01), erythrocyte sedimentation rate (ESR, p = 0.01), and IL-6 (p = 0.008) in AS, and with IL-6 (p = 0.001) in SAPHO. Serum ET-1 levels were lower in AS (p = 0.0005) than in controls. ET-1 positively correlated with ESR (p = 0.04) and Disease Activity Score 28 (DAS28, p = 0.003) in PsA. In spondyloarthritis, markers of endothelial function correlated with disease activity and TC.
- Published
- 2016
- Full Text
- View/download PDF
19. Serum VEGF, EGF, basic FGF, and acidic FGF levels and their association with disease activity and extra‑articular symptoms in ankylosing spondylitis.
- Author
-
Przepiera-Będzak H, Fischer K, and Brzosko M
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Epidermal Growth Factor blood, Fibroblast Growth Factor 1 blood, Fibroblast Growth Factor 2 blood, Spondylitis, Ankylosing blood, Vascular Endothelial Growth Factor A blood
- Published
- 2016
- Full Text
- View/download PDF
20. Extra-Articular Symptoms in Constellation with Selected Serum Cytokines and Disease Activity in Spondyloarthritis.
- Author
-
Przepiera-Będzak H, Fischer K, and Brzosko M
- Subjects
- Adult, Endothelin-1 blood, Epidermal Growth Factor blood, Female, Humans, Interleukin-18 blood, Interleukin-23 blood, Interleukin-6 blood, Male, Middle Aged, Risk, Uveitis, Anterior blood, Vascular Endothelial Growth Factor A blood, Acquired Hyperostosis Syndrome blood, Arthritis, Psoriatic blood, Cytokines blood, Spondylitis, Ankylosing blood
- Abstract
Objectives. In this study, we assessed the extra-articular symptoms in constellation with selected serum cytokines and disease activity in spondyloarthritis (SpA). Patients and Methods. We studied 287 SpA patients: 131 had AS, 110 had PsA, and 46 had SAPHO. We assessed extra-articular symptoms in all cases. In 191 SpA patients, we measured serum interleukin-6 (IL-6), interleukin-18 (IL-18), interleukin-23 (IL-23), endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). Results. Patients with acute anterior uveitis (AAU) had higher VAS ( P = 0.0008), BADSDAI ( P = 0.0001), ASDAS-ESR ( P = 0.04), CRP ( P = 0.006), IL-6 ( P = 0.02), and IL-18 ( P = 0.03) levels. Patients with inflammatory bowel disease (IBD) had higher VAS ( P = 0.03), CRP ( P = 0.0009), and IL-6 ( P = 0.0003) levels. Patients with skin psoriasis had lower VAS ( P = 0.001) and BASDAI ( P = 0.00007) levels. Patients with psoriatic onycholysis had lower VAS ( P = 0.006), BASDAI ( P = 0.00001), and CRP ( P = 0.02) and higher IL-23 ( P = 0.04) levels. Patients with PPP had lower BASDAI ( P = 0.04) and higher ET-1 ( P = 0.001) levels. Conclusions. SpA patients with increased serum IL-18 and decreased serum ET-1 had an increased risk of extra-articular symptoms. In SpA patients, increased disease activity was associated with an increased risk of AAU and IBD and a decreased risk of skin psoriasis, psoriatic onycholysis, and PPP., Competing Interests: The authors declare that they have no competing interests.
- Published
- 2016
- Full Text
- View/download PDF
21. Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome.
- Author
-
Przepiera-Będzak H, Fischer K, and Brzosko M
- Subjects
- Adult, Epidermal Growth Factor blood, Female, Fibroblast Growth Factors blood, Humans, Male, Middle Aged, Vascular Endothelial Growth Factor A blood, Acquired Hyperostosis Syndrome blood, Arthritis, Psoriatic blood, Cytokines blood, Interleukin-23 blood, Interleukin-6 blood, Spondylitis, Ankylosing blood
- Abstract
Objectives: To assess serum interleukin-6 (IL-6) and interleukin-23 (IL-23) and their correlation with angiogenic cytokines and disease activity in ankylosing spondylitis (AS), psoriatic arthritis (PsA), and SAPHO syndrome., Patients and Methods: We studied 152 spondyloarthritis (SpA) patients: 69 PsA, 61 AS, 22 SAPHO, and 29 controls. We recorded age, sex, disease duration, and treatment. We assessed BASDAI, VAS, and PASI scores. Serum IL-6, IL-23, VEGF, EGF, FGFb, and FGFa levels were determined using ELISA. We estimated ESR and CRP., Results: Serum IL-6 and IL-23 levels were higher in SpA than in control (P < 0.00001 and P = 0.0004, resp.). There was a positive correlation between serum IL-6 and CRP in AS (P = 0.000001), PsA (P = 0.000001), and SAPHO (P = 0.0003) patients. There was a positive correlation between serum IL-6 and ESR in AS (P = 0.000001), PsA (P = 0.002), and SAPHO (P = 0.02) patients. There was no correlation of serum IL-6 and IL-23 with VAS, BASDAI, and angiogenic cytokines in SpA., Conclusions: Serum IL-6 but not serum IL-23 correlated with ESR and CRP in SpA. No correlation was found of serum IL-6 and IL-23 with VAS, BASDAI, and angiogenic cytokines.
- Published
- 2015
- Full Text
- View/download PDF
22. Serum levels of angiogenic cytokines in psoriatic arthritis and SAPHO syndrome.
- Author
-
Przepiera-Będzak H, Fischer K, and Brzosko M
- Subjects
- Epidermal Growth Factor blood, Female, Fibroblast Growth Factor 1 blood, Fibroblast Growth Factor 2 blood, Humans, Male, Middle Aged, Platelet Count, Acquired Hyperostosis Syndrome blood, Arthritis, Psoriatic blood, C-Reactive Protein metabolism, Cytokines blood, Vascular Endothelial Growth Factor A blood
- Abstract
Introduction: Angiogenesis is involved in the pathogenesis of arthritis., Objectives: The aim of the study was to assess the serum levels of selected angiogenic cytokines and their association with clinical presentation in patients with psoriatic arthritis (PsA) and SAPHO syndrome., Patients and Methods: We studied 98 patients: 80 with PsA and 18 with SAPHO syndrome. The following data were recorded: age, sex, disease duration, joint involvement, type of psoriasis, nail involvement, and treatment. The following indices used to assess the activity of PsA and SAPHO were measured: PASI, BASDAI, BASFI, BASMI, BASG, and VAS pain. We determined erythrocyte sedimentation rate, C‑reactive protein (CRP), and platelet count. The serum levels of vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), basic and acidic fibroblast growth factors (FGFb and FGFa) were determined using an enzyme‑linked immunosorbent assay., Results: In patients with PsA, VEGF levels were positively correlated with CRP (P = 0.04), BASFI (P = 0.03), and disease duration (P = 0.007). No differences were found between patients with and without nail psoriasis in the VEGF or EGF levels (P = 0.32 and P = 0.85, respectively). There were no differences between patients with the peripheral and axial forms of arthritis in VEGF or EGF levels (P = 0.56 and P = 0.28, respectively). No significant correlations were observed between EGF and FGF levels and clinical presentation in patients with PsA. In patients with SAPHO, no significant correlations were found between angiogenic cytokine levels and clinical presentation., Conclusions: Our data suggest a role of VEGF in the pathogenesis of PsA. Further studies are required to better understand the role of angiogenic cytokines in PsA.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.